
| • |
Completed a $10 million private placement financing with certain institutional and accredited investors. The Company intends to use the net proceeds from the
financing to support the manufacturing and regulatory work needed to advance GTx-104.
|
| • |
Announced receipt of the FDA meeting minutes from a Type A Meeting held with the FDA to discuss the CRL issued on April 23, 2026. The
FDA did not identify any clinical safety or efficacy deficiencies and did not request additional clinical data. The Company is working on its previously disclosed plan to address the identified issues and will report progress as key
milestones are achieved.
|
| • |
Initiated a dual-source manufacturing strategy for GTx-104 to address potential remediation issues from its current contract
manufacturing organization (CMO). The Company’s current CMO has responded to the FDA, submitted a corrective action plan, and, the Company believes, is executing that plan in direct communication with the FDA. Reinspection timing depends
on the current CMO’s readiness and FDA scheduling. In parallel, technology transfer was initiated during the quarter ended September 30, 2026 to a second, U.S.-based CMO, starting with analytical method transfer. The Company has also
initiated the required non-clinical studies. The NDA resubmission may be supported by either CMO, or both, and its timing will reflect the pathway that reaches readiness first.
|


|
Grace Therapeutics Contact:
|
|
|
Prashant Kohli
|
|
|
Chief Executive Officer
|
|
|
Tel: 609-322-1602
|
|
|
Email: info@gracetx.com
|
|
|
www.gracetx.com
|
|
|
Investor Relations:
|
|
|
LifeSci Advisors
|
|
|
Mike Moyer
|
|
|
Managing Director
|
|
|
Phone: 617-308-4306
|
|
|
Email: mmoyer@lifesciadvisors.com
|

|
September 30, 2026
|
March 31, 2026
|
|||||||
|
(Expressed in thousands except share data)
|
$ |
$ |
||||||
|
Assets
|
||||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
21,311
|
16,977
|
||||||
|
Receivables
|
20
|
20
|
||||||
|
Prepaid expenses
|
629
|
383
|
||||||
|
Total current assets
|
21,960
|
17,380
|
||||||
|
Equipment, net
|
5
|
8
|
||||||
|
Intangible assets
|
27,595
|
41,128
|
||||||
|
Goodwill
|
8,138
|
8,138
|
||||||
|
Total assets
|
57,698
|
66,654
|
||||||
|
Liabilities and Stockholders’ equity
|
||||||||
|
Current liabilities:
|
||||||||
|
Trade and other payables
|
1,614
|
2,146
|
||||||
|
Total current liabilities
|
1,614
|
2,146
|
||||||
|
Deferred tax liability
|
604
|
612
|
||||||
|
Total liabilities
|
2,218
|
2,758
|
||||||
|
Commitments and contingencies
|
||||||||
|
Stockholders’ equity:
|
||||||||
|
Preferred stock, $0.0001 par value per share; 10,000,000 authorized; none issued and outstanding as of
September 30, 2026 and March 31, 2026
|
—
|
—
|
||||||
|
Common stock, $0.0001 par value per share; 100,000,000 authorized; 21,035,930 and 16,024,026 shares
issued and outstanding as of September 30, 2026 and March 31, 2026, respectively
|
2
|
1
|
||||||
|
Additional paid-in capital
|
307,917
|
298,413
|
||||||
|
Accumulated other comprehensive loss
|
(6,038
|
)
|
(6,038
|
)
|
||||
|
Accumulated deficit
|
(246,401
|
)
|
(228,480
|
)
|
||||
|
Total stockholders’ equity
|
55,480
|
63,896
|
||||||
|
Total liabilities and stockholders’ equity
|
57,698
|
66,654
|
||||||

|
Three months ended
|
Six months ended
|
|||||||||||||||
|
September 30,
2026
|
September 30,
2025
|
September 30,
2026
|
September 30,
2025
|
|||||||||||||
|
(Expressed in thousands, except share and per share data)
|
||||||||||||||||
| $ |
$ |
$ |
$ |
|||||||||||||
|
Operating expenses
|
||||||||||||||||
|
Research and development expenses
|
(885
|
)
|
(568
|
)
|
(1,582
|
)
|
(1,523
|
)
|
||||||||
|
General and administrative expenses
|
(1,407
|
)
|
(1,961
|
)
|
(3,094
|
)
|
(4,096
|
)
|
||||||||
|
Impairment of intangible assets
|
—
|
—
|
(13,533
|
)
|
—
|
|||||||||||
|
Loss from operating activities
|
(2,292
|
)
|
(2,529
|
)
|
(18,209
|
)
|
(5,619
|
)
|
||||||||
|
Foreign exchange (loss) gain
|
(1
|
)
|
(8
|
)
|
(15
|
)
|
3
|
|||||||||
|
Change in fair value of derivative warrant liabilities
|
—
|
1,427
|
—
|
940
|
||||||||||||
|
Interest and other income, net
|
154
|
172
|
295
|
375
|
||||||||||||
|
Total other income, net
|
153
|
1,591
|
280
|
1,318
|
||||||||||||
|
Loss before income tax benefit
|
(2,139
|
)
|
(938
|
)
|
(17,929
|
)
|
(4,301
|
)
|
||||||||
|
Income tax benefit
|
8
|
—
|
8
|
—
|
||||||||||||
|
Net loss and total comprehensive loss
|
(2,131
|
)
|
(938
|
)
|
(17,921
|
)
|
(4,301
|
)
|
||||||||
|
Basic and diluted loss per share
|
|
($0.11
|
)
|
|
($0.06
|
)
|
|
($0.96
|
)
|
|
($0.27
|
)
|
||||
|
Weighted-average number of shares outstanding
|
20,116,776
|
15,924,522
|
18,701,159
|
15,924,522
|
||||||||||||